Marketing & Sales

Navamedic announces $7.2m cash offer for Sensidose acquisition

Nordic pharma company Navamedic ASA has offered $7.2m (SEK75m) to purchase all shares in Sweden-based pharmaceutical firm Sensidose AB.

OncoVent signs agreement with Orient EuroPharma for oregovomab

Shenzhen Hepalink Pharmaceutical Group’s subsidiary OncoVent has entered into a licence and distribution agreement with Orient EuroPharma (OEP) for the immunotherapeutic drug candidate, oregovomab.

Adaptimmune and Genentech partner on allogeneic cell therapies

Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, for the development and commercialisation of allogeneic cell therapies across several cancer indications.

SciNeuro and Eli Lilly sign exclusive license agreement for alpha-synuclein in Greater China

Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.

Anima signs new strategic collaboration deal with Takeda

Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases.

Boston Pharmaceuticals signs three-year agreement with GSK

The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK).

Pfizer, BioNTech to supply 200 million more Covid-19 vaccine doses to Europe

Pfizer and BioNTech have entered into an agreement with the European Commission (EC) to supply an additional 200 million doses of their Covid-19 vaccine.

Merck announces supply agreement with US for initial doses of investigational biological therapy to treat Covid-19

Merck, known as MSD outside the United States and Canada, announced it has entered into an agreement with the United States Government to support the development, manufacture and initial distribution of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon approval or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

Pfizer, BioNTech agree to supply additional 100 million Covid-19 vaccine doses to US

Pfizer and BioNTech have entered into a second agreement with the US government to supply an additional 100 million doses of their Covid-19 vaccine.